Thanks for the link Drano, the editorial is on point. It is not a Cytodyn priority but given there is allocated money under NAAID/NIH I did file under the RECOVER request for information initiative with a direct pointer to Cytodyn if further interested. Here we have a company that has completed a phase 2 study, which is on a different level than “I have an idea.” This little nugget from the article puts a spotlight on what will likely be at the heart of future treatments.

“immune dysfunction will prove to be a key part of the answer.“